Health
Bavarian Nordic Shares Surge Amid Rising Mpox Vaccine Orders and Strong Q2 Earnings

Danish biotech giant Bavarian Nordic saw its shares rise on Thursday following the announcement of increased European orders for its Mpox vaccine and a better-than-expected second-quarter earnings report. The company’s robust performance has prompted an upward revision in its 2024 financial guidance, with earnings now expected to hit the higher end of the projected range.
For the full year 2024, Bavarian Nordic anticipates earnings before interest, taxes, depreciation, and amortization (EBITDA) to reach approximately DKK 1,350 million (€180.91 million), while total revenue is projected to be around DKK 5,300 million (€710.38 million). The company’s strong financial outlook is largely attributed to its recent success in securing a 440,000-dose contract for smallpox and Mpox vaccines from an unnamed European country.
This surge in demand for Mpox vaccines across Europe likely stems from heightened efforts by various countries to enhance early preparedness in response to the global Mpox outbreak in 2022. Bavarian Nordic’s Mpox vaccine, JYNNEOS—also known as Imvamune and Imvanes—is one of only two Mpox vaccines approved by the U.S. Food and Drug Administration (FDA). It is also recommended by the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE).
Paul Chaplin, President and CEO of Bavarian Nordic, expressed satisfaction with the company’s progress in the first half of 2024. “We are pleased to report strong developments for Bavarian Nordic during the first half of 2024. Unfortunately, Mpox is again making global headlines due to the record number of cases reported in Africa,” Chaplin said.
He also highlighted the company’s expanding partnership with the Africa Centres for Disease Control and Prevention (Africa CDC), focusing on vaccine supply and manufacturing within the continent. In response to the recent spike in Mpox cases, Bavarian Nordic plans to ramp up vaccine production to ensure equitable access, with the capacity to produce about 10 million doses by the end of next year and potentially deliver up to 2 million doses by the end of 2024.
The urgency surrounding Mpox vaccination has intensified following the WHO’s recent declaration of a new strain of Mpox as a public health emergency of international concern (PHEIC). This marks the first such declaration since May 2022, as the new strain has led to a rise in cases in countries previously unaffected by the virus, including Rwanda, Uganda, Burundi, and Kenya.
Professor Dimie Ogoina, speaking on behalf of the WHO, underscored the global significance of the current Mpox upsurge, particularly in Africa. WHO Regional Director for Africa, Dr. Matshidiso Moeti, emphasized ongoing efforts to combat the outbreak through coordinated international action, highlighting the importance of collaboration with communities and governments to bring the crisis under control.
As Bavarian Nordic continues to scale up its vaccine production, the company is poised to play a critical role in addressing the growing Mpox threat on a global scale.
Health
Europe Faces Growing Challenges in Meeting Medical Care Needs, EU Report Shows

A new report has highlighted stark disparities in healthcare access across Europe, revealing that a growing number of citizens face unmet medical needs due to systemic issues such as high costs and long waiting times.
According to the latest data from Eurostat and the Health at a Glance: Europe 2024 report, 3.8 per cent of EU residents aged 16 and over reported unmet medical needs in the past year. However, the percentage climbs significantly when focusing solely on individuals who actively required healthcare services — with some countries reporting unmet needs among over 20 per cent of this group.
The causes are twofold: healthcare system barriers, including long waiting lists and treatment costs, account for 2.4 per cent of all cases, while 1.4 per cent stem from personal reasons such as fear of doctors, lack of time, or lack of knowledge about available care.
Unmet healthcare needs vary widely across the continent. Estonia tops the list within the EU, with 15.5 per cent of people reporting unmet needs, followed closely by Greece and Albania, each over 13 per cent. Even wealthier Nordic countries show surprising figures — Denmark (12.2 per cent), Finland, and Norway (over 7.5 per cent) — despite high healthcare spending. Conversely, countries such as Germany (0.5 per cent), Austria (1.3 per cent), and the Netherlands (1.4 per cent) report the lowest levels, pointing to more efficient and accessible healthcare systems.
Cost is a dominant barrier in nations like Greece and Albania, where over 9 per cent of citizens cited unaffordable care. In contrast, long waiting times are the primary issue in countries like Estonia (12 per cent) and Finland (7.5 per cent).
Income inequality also plays a major role. On average, 3.8 per cent of low-income individuals across the EU report unmet needs due to healthcare system issues — more than triple the 1.2 per cent reported by higher-income groups. In Greece, that gap is particularly wide, with 23 per cent of low-income respondents affected.
Healthcare experts say these disparities reflect more than just economic factors. Dr. Tit Albreht, President of the European Public Health Association (EUPHA), noted, “Unmet health needs arise from different reasons, including how well healthcare governance integrates services to meet population needs.”
Industry leaders, such as Tina Taube of the European Federation of Pharmaceutical Industries and Associations (EFPIA), stressed the importance of timely access to diagnosis and treatment. “Unmet needs are context-specific,” she said. “It’s not just about product availability, but also healthcare system readiness.”
Andy Powrie-Smith of EFPIA added that patients in some European countries wait up to seven times longer than others for the same treatments due to regulatory delays and varying national infrastructures.
The findings underscore the need for a more coordinated, equitable healthcare strategy across the continent, especially as Europe faces the challenges of an ageing population and increasingly complex medical technologies.
Health
Chinese Nationals Charged in U.S. with Smuggling Toxic Fungus Labeled a Potential Agroterrorism Threat

U.S. federal authorities have charged two Chinese nationals in connection with smuggling a dangerous agricultural fungus into the country, a move investigators describe as posing significant national security risks.
Yunqing Jian, 33, and Zunyong Liu, 34, are accused of conspiracy, smuggling, making false statements, and visa fraud after allegedly attempting to bring Fusarium graminearum — a toxic fungus capable of devastating crops and harming humans and livestock — into the United States. The case was detailed in a court filing by the Federal Bureau of Investigation (FBI) in Detroit.
The fungus, which targets essential food staples like wheat, maize, barley, and rice, is described in a scientific journal cited by the FBI as a “potential agroterrorism weapon.” Experts warn that its spread could inflict serious damage on global food security and agricultural economies.
U.S. Attorney Jerome Gorgon Jr. emphasized the seriousness of the case, stating: “The alleged actions of these Chinese nationals, including a loyal member of the Chinese Communist Party, are of the gravest national security concerns.”
Jian made her first appearance in a Detroit federal court on Tuesday and remains in custody awaiting a bond hearing scheduled for Thursday. A court-appointed attorney for her initial appearance declined to comment.
According to the FBI’s complaint, the investigation began in July 2024 when Liu was stopped at Detroit Metropolitan Airport. During a routine screening, customs officials discovered suspicious red plant material in his backpack. Liu initially claimed not to know what it was but later admitted he planned to use it for research purposes at the University of Michigan, where Jian is currently employed and where Liu previously worked.
Authorities say Liu’s mobile phone contained an article titled “Plant-Pathogen Warfare under Changing Climate Conditions,” raising further concerns about the intended use of the samples. The FBI believes the two individuals were coordinating to introduce the pathogen into a U.S. research setting without proper clearance or oversight.
Liu was denied entry to the U.S. and deported in July. Charges against both individuals were filed this week, as prosecutors continue to investigate the scope of the alleged conspiracy.
The case underscores growing concerns in the U.S. over biosecurity and potential misuse of scientific research amid rising geopolitical tensions.
Health
US Expands Measles Vaccination Guidance Amid Global Surge in Cases
-
Business1 year ago
Saudi Arabia’s Model for Sustainable Aviation Practices
-
Business1 year ago
Recent Developments in Small Business Taxes
-
Politics1 year ago
Who was Ebrahim Raisi and his status in Iranian Politics?
-
Business11 months ago
Carrectly: Revolutionizing Car Care in Chicago
-
Business11 months ago
Saudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Technology1 year ago
Comparing Apple Vision Pro and Meta Quest 3
-
Politics1 year ago
Indonesia and Malaysia Call for Israel’s Compliance with ICJ Ruling on Gaza Offensive
-
Sports10 months ago
Keely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m